Najeeb Ali is a founding member of the Medtech practice at Centerview Partners. He has 20 years of experience as a strategic advisor to healthcare companies across medical device, life sciences/diagnostics, specialty pharma, and services sectors. Over the course of his career, Mr. Ali has engaged with clients on a broad range of complex strategic transactions, spin-offs and carve-outs, buy-side and sell-side mergers and acquisitions, divestitures, debt and equity financings, and partnerships.

Medical Device and LS/Dx – Advised BK Medical on its $1.5 billion sale to GE; Wright Medical on its $5.4 billion sale to Stryker; Zimmer Biomet on its spin-off of ZimVie; Danaher on its carve-out IPO and split-off of Envista; Becton Dickinson on its $3.0 billion mandatory preferred equity raise; Envista on its $600 million acquisition of Carestream Dental’s intra-oral scanner business from Clayton, Dubilier & Rice and $455 million sale of its KaVo business to Planmeca; Enovis (formerly Colfax) on its $3.2 billion acquisition of DJO Global from Blackstone; and Covidien on its spin-off of Mallinckrodt

Specialty Pharma – Advised Amneal on its $6.4 billion merger with Impax Labs; Altaris Capital on its $1.6 billion acquisition of Padagis, formerly Perrigo’s generic prescription pharmaceuticals division; Par Pharmaceuticals on its $1.9 billion sale to TPG and subsequent $8.1 billion sale to Endo International; and Gavis Pharmaceuticals on its $880 million sale to Lupin

Healthcare Services – Cardinal Health on its $1.0 billion sale of Cordis business to Hellman & Friedman; Blackstone, Carlyle, and Hellman & Friedman on its $34 billion acquisition of Medline Industries; and PharMEDium on its $2.6 billion sale to AmerisourceBergen

Prior to joining Centerview in 2022, Mr. Ali spent 18 years at J.P. Morgan, most recently as a Managing Director within its Healthcare business.

Mr. Ali received his Bachelor of Science and a Master of Business Administration in Finance from Kelley School of Business at Indiana University Bloomington.